Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML

Zherou He, Qing Zhang, Xuan Zhou, Qiang Wang, Xiaoli Liu, Na Xu

Blood (2024) 144 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2024-207302

Published: 2024

Journal Articles

The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Ziyu Wen, Xuan Zhou, Bingyu Lin, Xiaoli Liu, Qiang Wang, Na Xu

Blood (2024) 144 (Supplement 1): 1803.

https://doi.org/10.1182/blood-2024-205725

Published: 2024

Journal Articles

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Zicheng Gao, Xuan Zhou, Qiang Wang, Dan Xu, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2024) 144 (Supplement 1): 6643.

https://doi.org/10.1182/blood-2024-207289

Published: 2024

Journal Articles

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

Ziyu Wen, Xuan Zhou, Bingyu Lin, Xiaoli Liu, Qiang Wang, Na Xu

Blood (2024) 144 (Supplement 1): 6639.

https://doi.org/10.1182/blood-2024-205673

Published: 2024

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao

Blood (2024) 144 (Supplement 1): 477.

https://doi.org/10.1182/blood-2024-205300

Published: 2024

Journal Articles

Analysis the Relationship between Clonal Hematopoiesis and Cardiovascular Events in Chronic Myeloid Leukemia Based on Next-Generation Sequencing Technology

Jie Luo, Ziyu Wen, Mengxia Zhao, Zicheng Gao, Hong Chen, Qiang Wang, Xuan Zhou, Zherou He, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2023-182007

Published: 2023

Journal Articles

Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study

Ziyu Wen, Zhiping Fan, Qiang Wang, Xuan Zhou, Zherou He, Zicheng Gao, Hong Chen, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Hongsheng Zhou, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 4538.

https://doi.org/10.1182/blood-2023-181850

Published: 2023

Journal Articles

Ruxolitinib or Interferon-α Treatment As a Protective Strategy for Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN) during the COVID-19 Pandemic

Zicheng Gao, Zherou He, Xuan Zhou, Ziyu Wen, Hong Chen, Qiang Wang, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 6411.

https://doi.org/10.1182/blood-2023-184700

Published: 2023

Journal Articles

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Bailin He, Hongsheng Zhou, Ren Lin, Zhixiang Wang, Na Xu, Qiang Wang, Jing Sun, Xiaoli Liu, Peng Li, Qifa Liu

Blood (2023) 142 (Supplement 1): 3484.

https://doi.org/10.1182/blood-2023-184492

Published: 2023

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Qian Jiang, Yanli Zhang, Qiang Wang, Jianyu Weng, Zhenfang Liu, Suning Chen, Li Weiming, Bingcheng Liu, Zhuogang Liu, Yihan Wang, Jingrong Cao

Blood (2023) 142 (Supplement 1): 867.

https://doi.org/10.1182/blood-2023-185977

Published: 2023

Journal Articles

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

Xuan Zhou, Na Xu, Ziyu Wen, Hanyin Liang, Dongmei Luo, Hong Chen, Zherou He, Zicheng Gao, Qiang Wang, Dan Xu, Xiaoli Liu, Qifa Liu

Blood (2023) 142 (Supplement 1): 6379.

https://doi.org/10.1182/blood-2023-184643

Published: 2023

Journal Articles

TKI Dose Optimization Based on Therapeutic Drug Monitoring（TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients

Zherou He, Xuan Zhou, Ziyu Wen, Zicheng Gao, Hong Chen, Qiang Wang, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2023) 142 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2023-182765

Published: 2023

Journal Articles

Patient-Versus Physician-Perceptions of Symptoms, Treatment and Management in Chronic Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 10841–10842.

https://doi.org/10.1182/blood-2022-157246

Published: 2022

Journal Articles

Single-Cell RNA Profiling of Primary Myelofibrosis Reveals RUX Resistance Decreasing Mononuclear Phagocytes in Peripheral Blood

Luo Dongmei, Na Xu, Xiaoli Liu, Jie Luo, Hanyin Liang, Zherou He, Hong Chen, Qiang Wang, Xuan Zhou

Blood (2022) 140 (Supplement 1): 6755–6756.

https://doi.org/10.1182/blood-2022-165137

Published: 2022

Journal Articles

RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway

Qiang Wang, Zhijuan Lin, Zhuo Wang, Lingqun Ye, Miao Xian, Liuling Xiao, Pan Su, Enguang Bi, Yung-hsing Huang, Jianfei Qian, Lintao Liu, Xingzhe Ma, Maojie Yang, Wei Xiong, Youli Zu, Sai Ravi Pingali, Bing Xu, Qing Yi

Blood (2022) 139 (1): 59–72.

https://doi.org/10.1182/blood.2020009856

Published: 2022

Includes: Supplemental data

Journal Articles

MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma

Qiang Wang, Dongyu Zhao, Miao Xian, Zhuo Wang, Enguang Bi, Pan Su, Jianfei Qian, Xingzhe Ma, Maojie Yang, Lintao Liu, Youli Zu, Sai Ravi Pingali, Kaifu Chen, Zhen Cai, Qing Yi

Blood (2020) 136 (22): 2557–2573.

https://doi.org/10.1182/blood.2020005795

Published: 2020

Includes: Supplemental data

Journal Articles

RAR Gamma Activation Sensitizes Human Myeloma Cells to Carfilzomib Treatment through OAS-RNase L Innate Immune Pathway

Qiang Wang, Zhijuan Lin, MD, Qing Yi, MD PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-133970

Published: 2020

Journal Articles

Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants

Blood (2019) 134 (Supplement_1): 188.

https://doi.org/10.1182/blood-2019-131781

Published: 2019

Journal Articles

Development of an Immunotherapeutic Monoclonal Antibody Recognizing DKK1-HLA-A2 Complex to Treat Human Hematologic Malignancies

Jianfei Qian, PhD, Qiang Wang, PhD, Lintao Liu, PhD, Enguang Bi, PhD, Xingzhe Ma, PhD, Pan Su, PhD, Maojie Yang, Qing Yi, MD PhD

Blood (2019) 134 (Supplement_1): 5551.

https://doi.org/10.1182/blood-2019-123541

Published: 2019

Journal Articles

A Novel Oral Histone Deacetylase Inhibitor Chidamide Is Highly Effective and Well-Tolerated in Adult Early T-Cell Precursor and Ph-like Acute Lymphoblastic Leukemia

Hongsheng Zhou, MD PhD, Ya Gao, MD, Qiang Wang, Rui Cao, Zhongxin Zhen, Qiuli Li, Dainan Lin, Linlin Zhou, Changxin Yin, Han He, Xiaoli Liu, Bing Z Carter, PhD, Qifa Liu, MD

Blood (2018) 132 (Supplement 1): 4011.

https://doi.org/10.1182/blood-2018-99-113712

Published: 2018

NARROW

Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML

The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Analysis the Relationship between Clonal Hematopoiesis and Cardiovascular Events in Chronic Myeloid Leukemia Based on Next-Generation Sequencing Technology

Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study

Ruxolitinib or Interferon-α Treatment As a Protective Strategy for Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN) during the COVID-19 Pandemic

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

TKI Dose Optimization Based on Therapeutic Drug Monitoring（TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients

Patient-Versus Physician-Perceptions of Symptoms, Treatment and Management in Chronic Myeloid Leukemia

Single-Cell RNA Profiling of Primary Myelofibrosis Reveals RUX Resistance Decreasing Mononuclear Phagocytes in Peripheral Blood

RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway

MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma

RAR Gamma Activation Sensitizes Human Myeloma Cells to Carfilzomib Treatment through OAS-RNase L Innate Immune Pathway

Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants

Development of an Immunotherapeutic Monoclonal Antibody Recognizing DKK1-HLA-A2 Complex to Treat Human Hematologic Malignancies

A Novel Oral Histone Deacetylase Inhibitor Chidamide Is Highly Effective and Well-Tolerated in Adult Early T-Cell Precursor and Ph-like Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only